These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 20495920

  • 1. In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
    Cheng H, An SJ, Zhang XC, Dong S, Zhang YF, Chen ZH, Chen HJ, Guo AL, Lin QX, Wu YL.
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):637-46. PubMed ID: 20495920
    [Abstract] [Full Text] [Related]

  • 2. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S, Zhang XC, Cheng H, Zhu JQ, Chen ZH, Zhang YF, Xie Z, Wu YL.
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [Abstract] [Full Text] [Related]

  • 3. The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
    Jiang Y, Li C, Ma Y, Chen J, Li Y, Chen L.
    Clin Lab; 2012 Nov; 58(5-6):551-61. PubMed ID: 22783588
    [Abstract] [Full Text] [Related]

  • 4. Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Jun; 9(6):2417-22. PubMed ID: 24682085
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA.
    Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836
    [Abstract] [Full Text] [Related]

  • 6. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
    Chen B, Zheng J, Zeng Y, Li B, Xie B, Zheng J, Zhou J, Zhang W.
    PLoS One; 2014 Dec 01; 9(12):e114074. PubMed ID: 25474307
    [Abstract] [Full Text] [Related]

  • 7. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
    Liu H, Li L, Li XQ, Liu XJ, Zhen YS.
    Anticancer Drugs; 2009 Jan 01; 20(1):41-9. PubMed ID: 19342999
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.
    Shen H, Yuan Y, Sun J, Gao W, Shu YQ.
    Biomed Pharmacother; 2010 Feb 01; 64(2):88-92. PubMed ID: 20005069
    [Abstract] [Full Text] [Related]

  • 10. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT, Li WC, Gao S, Wang F, Li XQ, Yu HQ, Fan LL, Wei W, Wang H, Sun GP.
    Clin Lung Cancer; 2015 Sep 01; 16(5):e55-66. PubMed ID: 25979647
    [Abstract] [Full Text] [Related]

  • 11. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

  • 12. Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor.
    Fung AS, Yu M, Ye QJ, Tannock IF.
    Cancer Chemother Pharmacol; 2013 Sep 01; 72(3):585-95. PubMed ID: 23851981
    [Abstract] [Full Text] [Related]

  • 13. Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
    Tsai CM, Chen JT, Stewart DJ, Chiu CH, Lai CL, Hsiao SY, Chen YM, Chang KT.
    J Thorac Oncol; 2011 Mar 01; 6(3):559-68. PubMed ID: 21258258
    [Abstract] [Full Text] [Related]

  • 14. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Aug 01; 10(2):931-8. PubMed ID: 24840891
    [Abstract] [Full Text] [Related]

  • 15. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
    Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, Krozely P, Sandler A, Carbone D, Heelan RT, Kris MG, Smith R, Ochs J.
    J Clin Oncol; 2003 Jun 01; 21(11):2094-100. PubMed ID: 12775734
    [Abstract] [Full Text] [Related]

  • 16. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
    Wang MC, Liang X, Liu ZY, Cui J, Liu Y, Jing L, Jiang LL, Ma JQ, Han LL, Guo QQ, Yang CC, Wang J, Wu T, Nan KJ, Yao Y.
    Oncol Rep; 2015 Jan 01; 33(1):239-49. PubMed ID: 25370413
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
    Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, Dimitroulakos J.
    Clin Cancer Res; 2005 Mar 15; 11(6):2398-407. PubMed ID: 15788691
    [Abstract] [Full Text] [Related]

  • 19. Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.
    Tsai CM, Chiu CH, Chang KT, Chen JT, Lai CL, Chen YM, Hsiao SY.
    J Thorac Oncol; 2012 Aug 15; 7(8):1218-27. PubMed ID: 22659964
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.